SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-141816
Filing Date
2024-05-17
Accepted
2024-05-17 16:45:56
Documents
13
Period of Report
2024-05-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d800582d8k.htm   iXBRL 8-K 25015
  Complete submission text file 0001193125-24-141816.txt   151163

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fnch-20240514.xsd EX-101.SCH 2869
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fnch-20240514_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fnch-20240514_pre.xml EX-101.PRE 11720
16 EXTRACTED XBRL INSTANCE DOCUMENT d800582d8k_htm.xml XML 3768
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40227 | Film No.: 24960644
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)